ReviewCancer management and research2018

Hematologic toxicity is rare in relapsed patients treated with belinostat: a systematic review of belinostat toxicity and safety in peripheral T-cell lymphomas.

Pamela B Allen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.